Glatiramer Acetate — Drug Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

5 Recruiting

7 Completed trials

11 Sponsors

17 Countries

Phase III

Phase II

Phase I/II

Phase III: 8 Phase II: 3 Phase I/II: 2

Oversight events:

1 unexpected event across 1 trial

View oversight register →

Indications tested

Secondary progressive multiple sclerosis 2 Triple negative breast cancer 2 Multiple sclerosis 1 Ovarian cancer 1 Relapsing-remitting multiple sclerosis 1 Non-small cell lung cancer metastatic 1 Myelofibrosis 1 Progressive multiple sclerosis 1 Multiple sclerosis relapse 1 Primary progressive multiple sclerosis 1

Sponsors using this IMP

Centre Hospitalier Universitaire De Nantes 2 Merck Sharp & Dohme LLC 2 Antwerp University Hospital 1 Bolt Biotherapeutics Inc. 1 Celgene Corp. 1 Champalimaud Clinical Centre 1 F. Hoffmann-La Roche AG 1 Genmab A/S 1 Heinrich-Heine-Universitaet Duesseldorf 1 Les Hopitaux Universitaires De Strasbourg 1 Novartis Pharma AG 1

All trials

13 total

DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending

2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Phase III 12 countries Genmab A/S
CATALINA-2: A Phase 2 Study of TORL-1-23 in Advanced Ovarian Cancer Recruiting

2024-517190-24-00 Phase II 8 countries Torl Biotherapeutics LLC
DISEASE MODIFYING THERAPIES WITHDRAWAL IN INACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS AGED 55 AND OVER: A MULTICENTRIC, RANDOMI… Recruiting

2024-513475-41-00 Phase III 1 country Les Hopitaux Universitaires De Strasbourg
Study to compare the activation of the immune system depending on the chemotherapy scheme used together with PEMBROLIZUM (immunotherapy) in … Recruiting

2023-507008-30-00 Phase II 1 country Champalimaud Clinical Centre
Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting

2024-514688-24-00 Phase I/II 1 country Heinrich-Heine-Universitaet Duesseldorf
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Phase II 1 country Antwerp University Hospital
Clinical Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) versus Intravenous Pembrolizumab, Given with Chemoth… Ended

2022-501506-36-00 Phase III 5 countries Merck Sharp & Dohme LLC
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Ved… Ended

2023-506986-74-00 Phase I/II 2 countries F. Hoffmann-La Roche AG
STOP-I-SEP_Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Ended

2024-516628-32-00 Phase III 1 country Centre Hospitalier Universitaire De Rennes
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 Phase III 4 countries Novartis Pharma AG
A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended

2024-511972-33-00 Phase III 10 countries Celgene Corp.
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended

2022-501382-49-00 Phase III 8 countries Merck Sharp & Dohme LLC

Showing 1–13 of 13 trials

← All drugs A–Z